- Oops!Something went wrong.Please try again later.
Acasti Pharma (NASDAQ: ACST) shares are trading higher on Monday after B.Riley FBR upgraded the stock from Neutral to Buy and announced a price target of $2 per share.
Acasti Pharma is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk.
The company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia
Acasti Pharma shares were trading up 16.74% at 62 cents on Monday. The stock has a 52-week high of $3.08 and a 52-week low of 25 cents.
Latest Ratings for ACST
B. Riley FBR
View More Analyst Ratings for ACST
View the Latest Analyst Ratings
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.